Literature DB >> 19442168

The role of gut microbiota in drug response.

I D Wilson1, J K Nicholson.   

Abstract

Higher organisms such as mammals exist in a symbiotic relationship with their gut microbiota, formed from a diverse and highly metabolically active consortium of species. The gut microbiota, in addition to their ability to process dietary derived material, are also capable of performing a range of biotransformations on xenobiotics, such as drugs and their metabolites, in ways that can affect absorption and bioavailability. The potential for the gut microflora to influence drug metabolism and toxicity in unexpected ways is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442168     DOI: 10.2174/138161209788168173

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  29 in total

1.  Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.

Authors:  Ian D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

Review 2.  Gut microbiota: a key player in health and disease. A review focused on obesity.

Authors:  M J Villanueva-Millán; P Pérez-Matute; J A Oteo
Journal:  J Physiol Biochem       Date:  2015-03-08       Impact factor: 4.158

Review 3.  Understanding the apothecaries within: the necessity of a systematic approach for defining the chemical output of the human microbiome.

Authors:  Kirk Beebe; Brante Sampey; Steven M Watkins; Michael Milburn; Andrea D Eckhart
Journal:  Clin Transl Sci       Date:  2014-01-14       Impact factor: 4.689

Review 4.  Towards a predictive systems-level model of the human microbiome: progress, challenges, and opportunities.

Authors:  Sharon Greenblum; Hsuan-Chao Chiu; Roie Levy; Rogan Carr; Elhanan Borenstein
Journal:  Curr Opin Biotechnol       Date:  2013-04-23       Impact factor: 9.740

Review 5.  Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics.

Authors:  Marwa ElRakaiby; Bas E Dutilh; Mariam R Rizkallah; Annemarie Boleij; Jason N Cole; Ramy K Aziz
Journal:  OMICS       Date:  2014-05-02

6.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.

Authors:  Kyle S Saitta; Carmen Zhang; Kang Kwang Lee; Kazunori Fujimoto; Matthew R Redinbo; Urs A Boelsterli
Journal:  Xenobiotica       Date:  2013-07-05       Impact factor: 1.908

7.  Loss of function dysbiosis associated with antibiotics and high fat, high sugar diet.

Authors:  Aaron W Miller; Teri Orr; Denise Dearing; Manoj Monga
Journal:  ISME J       Date:  2019-01-30       Impact factor: 10.302

8.  Should the human microbiome be considered when developing vaccines?

Authors:  Rosana B R Ferreira; L Caetano M Antunes; B Brett Finlay
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

Review 9.  Asthma microbiome studies and the potential for new therapeutic strategies.

Authors:  Yvonne J Huang
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

10.  Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.

Authors:  Melissa K Friswell; Helen Gika; Ian J Stratford; Georgios Theodoridis; Brian Telfer; Ian D Wilson; Andrew J McBain
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.